We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+42.24%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$431M
AUM Growth
+$40.6M
Cap. Flow
-$22.4M
Cap. Flow %
-5.2%
Top 10 Hldgs %
39.17%
Holding
104
New
21
Increased
36
Reduced
26
Closed
21

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$12.5M
2
AMGN icon
Amgen
AMGN
+$10.8M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$4.35M
4
DHR icon
Danaher
DHR
+$3.96M
5
FOCL
EDAP TMS S.A.
FOCL
+$3.61M

Top Sells

Rank Stock Value
1
VCEL icon
Vericel Corp
VCEL
+$13.2M
2
SDGR icon
Schrodinger
SDGR
+$10.4M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$9.41M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$9.05M
5
GNMK
GenMark Diagnostics, Inc
GNMK
+$9.02M

Sector Composition

Rank Sector Weight
1 Healthcare 92.25%
2 Technology 1.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INFU icon
26
InfuSystem Holdings
INFU
$244M
$5.68M 1.32%
278,833
+37,322
+15% +$699K
GOSS icon
27
Gossamer Bio
GOSS
$86.8M
$5.39M 1.25%
582,890
+232,111
+66% +$2.34M
FOCL
28
EDAP TMS S.A.
FOCL
$178M
$4.82M 1.12%
573,374
+443,485
+341% +$3.61M
IONS icon
29
Ionis Pharmaceuticals
IONS
$9.39B
$4.76M 1.1%
105,797
+30,379
+40% +$1.69M
ARWR icon
30
Arrowhead Research
ARWR
$12.3B
$4.65M 1.08%
70,089
-57,082
-45% -$4.43M
MDGL icon
31
Madrigal Pharmaceuticals
MDGL
$12.4B
$4.65M 1.08%
39,721
+26,745
+206% +$3.12M
STRO icon
32
Sutro Biopharma
STRO
$353M
$4.61M 1.07%
20,270
-6,395
-24% -$1.52M
STXS icon
33
Stereotaxis
STXS
$139M
$4.54M 1.05%
675,922
+28,379
+4% +$168K
AXGN icon
34
Axogen
AXGN
$2.67B
$4.29M 1%
211,599
-18,910
-8% -$373K
BBIO icon
35
BridgeBio Pharma
BBIO
$16.4B
$4.01M 0.93%
65,174
-10,969
-14% -$718K
MRVI icon
36
Maravai LifeSciences
MRVI
$861M
$4.01M 0.93%
112,500
+2,224
+2% +$73.7K
NUAN
37
DELISTED
Nuance Communications, Inc.
NUAN
$3.98M 0.92%
91,173
-24,489
-21% -$1.13M
KOD icon
38
Kodiak Sciences
KOD
$2.72B
$3.75M 0.87%
33,048
-16,865
-34% -$2.3M
IDXX icon
39
Idexx Laboratories
IDXX
$45B
$3.73M 0.87%
7,632
+39
+0.5% +$19.5K
OM icon
40
Outset Medical
OM
$84.6M
$3.54M 0.82%
4,333
+2,452
+130% +$1.89M
SPNE
41
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$3.32M 0.77%
190,747
-184,198
-49% -$3.3M
KDMN
42
DELISTED
Kadmon Holdings, Inc.
KDMN
$3.21M 0.74%
824,475
-109,889
-12% -$503K
XRAY icon
43
Dentsply Sirona
XRAY
$2.27B
$3.19M 0.74%
+50,000
New +$2.9M
SDGR icon
44
Schrodinger
SDGR
$1.39B
$3.09M 0.72%
40,453
-115,632
-74% -$10.4M
HCAT icon
45
Health Catalyst
HCAT
$135M
$3.05M 0.71%
65,274
-9,726
-13% -$471K
COO icon
46
Cooper Companies
COO
$15B
$2.88M 0.67%
+30,000
New +$2.85M
BCRX icon
47
BioCryst Pharmaceuticals
BCRX
$2.71B
$2.49M 0.58%
244,680
-293,690
-55% -$3.03M
JAZZ icon
48
Jazz Pharmaceuticals
JAZZ
$16.2B
$2.47M 0.57%
+15,000
New +$2.47M
ETNB
49
DELISTED
89bio
ETNB
$2.42M 0.56%
102,163
+5,490
+6% +$127K
BCEL
50
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$2.33M 0.54%
151,993
+25,735
+20% +$418K
1
2
3 4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q1 2021 Portfolio in Review

As of Q1 2021, Parkman Healthcare Partners held 104 positions worth $431M, up 10% from $390M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Parkman Healthcare Partners withdrew a net $22.4M in Q1 2021, closing 21 positions and reducing 26 holdings. Its most notable exit was GW Pharmaceuticals Plc American Depositary Shares, an estimated $9.41M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 92% a quarter earlier, followed by Technology.

Against the trend, Parkman Healthcare Partners opened a new position in United Therapeutics worth $12.5M.

  • Parkman Healthcare Partners's largest Q1 2021 buy was United Therapeutics: 74,874 shares worth $12.5M.
  • Parkman Healthcare Partners added most to Alnylam Pharmaceuticals in Q1 2021, an estimated $4.35M increase.
  • Parkman Healthcare Partners's biggest Q1 2021 reduction was Vericel Corp, cutting an estimated $13.2M.
  • Parkman Healthcare Partners fully exited GW Pharmaceuticals Plc American Depositary Shares in Q1 2021, selling an estimated $9.41M.
  • Parkman Healthcare Partners's ten largest holdings make up 39% of its $431M portfolio in Q1 2021.
  • Parkman Healthcare Partners opened 21 new positions and closed 21 in Q1 2021.
  • Parkman Healthcare Partners's portfolio value rose 10% quarter-over-quarter to $431M.

Based on Parkman Healthcare Partners's 13F filing for Q1 2021, filed 14 May 2021.